Medifast, Inc. MED
12.20 USD +0.01 (+0.08%)
Regular-session close
12.20 0.00 0.00%
After hours · Nov 18, 4:00 PM ET
11.95 Day range 12.27
9.22 52-week range 13.63
- YTD
- +14.23%
- 1 year
- +9.12%
News
zacks.com Can Medifast's Coaching Model Complement GLP-1 Weight-Loss Drugs? MED is positioning Trilivy as a complement to GLP-1 medications, combining nutrition and coaching to support sustainable metabolic health and weight management.
benzinga.com Medifast Q3 2026 Earnings Call Transcript Medifast (NYSE:MED) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Medifast Lowers FY2026 GAAP EPS Guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) Est Medifast (NYSE:MED) lowers FY2026 GAAP EPS guidance from $(1.75)-$(0.25) to $(2.05)-$(1.80) vs $(0.94) analyst estimate..
benzinga.com Medifast Sees FY2026 Adj EPS $(0.70)-$(0.45) vs $(0.94) Est; Raises FY2026 Sales Guidance from $270.000M-$300.000M to $280.000M-$300.000M vs $287.700M Est Medifast (NYSE:MED) is looking for FY2026 Adj EPS of $(0.70)-$(0.45) vs $(0.94) analyst estimate. Raises FY2026 sales outlook from $270.000 million-$300.000 million to $280.000 million-$300.000…
benzinga.com Medifast Q3 Adj. EPS $(0.19) Beats $(0.35) Estimate, Sales $72.048M Beat $71.300M Estimate Medifast (NYSE:MED) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.35) by 45.71 percent. This is a 9.52 percent increase over losses of $(0.21) per…
benzinga.com Medifast Sees Q4 GAAP EPS $0.00-$0.25 vs $(0.12) Est; Sees Sales $55.000M-$75.000M vs $64.100M Est Medifast (NYSE:MED) is looking for Q4 GAAP EPS of $0.00-$0.25 vs $(0.12) analyst estimate. sees sales of $55.000 million-$75.000 million vs $64.100 million analyst estimate.
